



Eu2P

European programme in pharmacovigilance and pharmacoepidemiology




Coordinator: ROCHE - Deborah Szafir Managing entity: Université Bordeaux 2 - Annie Fourrier-Réglat



Disclaimer




- This document contains description of the Eu2P project work and management. Certain parts of this document might be under partner Intellectual Property Right (IPR) rules so, prior to using its content please contact the project management team for approval.
- e-mail: karine.palin@u-bordeaux2.fr & marie-christa.bataille@u-bordeaux2.fr
- In case you believe that this document harms in any way IPR held by you as a person or as representative of an entity, please do notify Eu2P project management team immediately.
- The authors of this document have taken any available measure in order for its content to be accurate, consistent and lawful. However, neither the project consortium as a whole nor the individual partners that implicitly or explicitly participated the creation and publication of this document hold any sort of responsibility that might occur as a result of using its content.
- This publication has been produced with the assistance of the Innovative Medicines Initiative Joint
 Undertaking (IMI JU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
 The content of this publication is the sole responsibility of the Eu2P consortium and can in no way be taken
 to reflect the views of the IMI JU and EFPIA.
- Eu2P is a project funded by the IMI JU and EFPIA partners.



What academia, industry and patients need What Europe needs




Let's watch the Eu2P video! (link)



What Eu2P will do about it?



- Respond to the growing need for well-trained professionals, specialists and non-specialists, in pharmacovigilance and pharmacoepidemiology
- Develop an educational curriculum with a high level of excellence
- Improve the understanding and the effectiveness of medicines risk communication
- Develop innovative, modular and interactive e-teaching and elearning methods



Eu2P innovative approach



- 1. A consortium gathering the best of the pharmaceutical industry, regulatory authorities and academia in the field
- 15 major pharmaceutical companies,
- The European medicines agency & French medicines agency,
- 7 European universities,
 the most famous ones in
 the field

Denmark

Lundbeck Novo Nordisk

Netherlands

University Erasmus Medical Center University of Utrecht

Belgium

Amgen Janssen Pharmaceutica UCB Pharma

United Kingdom

European Medicines Agency University of Hertfordshire Astra Zeneca Eli Lilly Glaxo Smith Kline

Sweden

Karolinska Institute

Finland

Orion Corporation

Germany

Bayer Schering Pharma Boehringer Ingelheim

Switzerland

Novartis Pharma

France

University Bordeaux 2, Managing Entity for the IMI-JU Funding Afssaos

Roche, Coordinator sanofi-aventis

Italy

University of Verona



Spain


Catalan Institute of Pharmacology Laboratories Almirall

Eu2P innovative approach



- 1. A consortium gathering the best of the pharmaceutical industry, regulatory authorities and academia in the field
- Close private-public partnership in the learning outcomes definition, in the course content deployment and in the internship follow-up
- For the first time ever,

Delivery of European joint certificates and diplomas - Master and PhD - recognised by a private-public partnership



Eu2P innovative approach



- 4. To target all stakeholders
 - The professionals
 - Non-specialists: journalists, venture capitalists, insurers...
 - Specialists: industry, regulatory and academic PV experts, biostatisticians, and healthcare providers...
 - The patients
 - The students
 - Graduate students in medicine, pharmacy, veterinary medicine and in other biological scientific fields
- 5. E-learning format: allows joint offer of the best experts in the field, but also on-the-job training
 - Sandwich course format: allows professional-based learning, eases access to the Master curriculum for professionals



Eu2P expected outcome



- To supply a comprehensive, multilevel and updated knowledge in pharmacovigilance and pharmacoepidemiology adapted to targeted specialists and non-specialists
- To provide a catalogue allowing the validation of
 - ✓ Certificates
 - ✓ Master degree
 - ✓ PhD degree
- To obtain a joint accreditation for the Eu2P diplomas in pharmacovigilance & pharmacoepidemiology
- To deploy an e-learning platform in order to deliver interactive and on-the-job training modules



Time and money



Financing

- IMI funding: 3.479.725 Euros
- EFPIA contribution, mainly in kind: 3.791.161 Euros
- Total project cost: 7.270.886 Euros

Timing:

- Starting date: 1st of September 2009
- Duration: 60 months



Eu2P planning and milestones



1st Phase:

 $1^{
m st}$ Sept 2009 - March 2011

- Establishment of the Eu2P programme
- e-Learning platform deployment
- Diploma Agreements (Master, PhD, certificates)

2nd Phase: April 2011 – Aug 2014

- Modular (in 1, 2 or 3 years) and flexible (anytime, anyplace) courses delivery: Master, PhD and certificates
- Evaluation and Quality control procedures
- Promotion and communication of Eu2P

End of the 5th year

Self-sustaining programme



Eu2P achievements so far



PROGRAMME: Programme content & architecture

establishment of the Eu2P catalogue

Eu2P	catal	loque

6 specialisations offered for Master


Benefit assessment
Regulatory aspects
Risk identification and
quantification
Benefit-risk assessment
Public health
Risk communication

28 certificates offered for specialists and non-specialists

i.e. introductory, intermediate and advanced courses

18 modules offered for PhD

i.e. intermediate and advanced courses




Eu2P achievements so far



PROGRAMME: Progress on the training organization


- Deployment of a Eu2P central office
 To manage trainees and trainers (application, registration, internship,...)
- Set up of the Eu2P e-learning platform: beta version
 Dokeos platform on Eu2P server and accessible to the Eu2P consortium to "play with"
 - Crossed negotiations with the Universities for joint diploma agreements
 - Check and validation of the accreditation procedures in each Eu2P partners country



How are we going to produce training contents?



3 types of formats that can be combined




Eu2P achievements so far



COMMUNICATION

- Logotype validated, Eu2P trademark registration underway
- Creation of Eu2P templates for slides and text documents
- Creation of a promotional video
- Private website and forum on-line (www.eu2p.eu/privateZone/)
- Public website in progress: www.eu2p.org





Expected benefit to patients



Eu2P trained health professionels will have a common European theoretical and practical understanding in medicines benefits and risks,

Professionals not directly related to health will get a chance to improve their knowledge about medicines benefits and risks,

Patients will get a chance to be trained in medicines risk communication,



Health professionals together will be more efficient and coordinated in Europe




Non-health professionals and patients will be better informed, more familiar with medicines & better health-protected



Eu2P Consortium







Further information



- Contact : contact@eu2p.org
- Eu2P project website: www.eu2p.org
- Eu2P video avalaible on YouTube

www.imi.europa.eu

